Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRDF with free AI briefings, catalyst countdowns, and dilution alerts.

CRDF · Cardiff Oncology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$39.9M Cash on Hand
11.1mo Cash Runway
Follow CRDF by email Get an email when CRDF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRDF, unsubscribe in one click. Privacy

📣 What CRDF Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Capivasertib (AZD5363) Estrogen Receptor Positive Breast Cancer Phase 1/2 · NCT01992952 Active not recruiting
Cediranib Bowel Obstruction Phase 2 · NCT07648745 Completed
FOLFIRI Metastatic Colorectal Cancer Phase 2 · NCT06106308 Active not recruiting
FOLFOX Metastatic Colorectal Cancer Phase 2 · NCT06106308 Active not recruiting
NALIRIFOX Pancreatic Cancer Phase 1/2 · NCT06736717 Active not recruiting
Irinotecan Sucrosofate Pancreatic Ductal Adenocarcinoma Phase 2 · NCT04752696 Terminated
Onvansertib Small-cell Lung Cancer Phase 2 · NCT05450965 Recruiting
Saruparib Locally Advanced Pancreatic Ductal Adenocarcinoma Early Phase 1 · NCT04005690 Recruiting
Azenosertib Locally Advanced Pancreatic Ductal Adenocarcinoma Early Phase 1 · NCT04005690 Recruiting

Also used in these trials (approved or third-party drugs, not CRDF's own candidates): Carvedilol, Bevacizumab, Fluorouracil, Fulvestrant, Leucovorin, Paclitaxel, Pembrolizumab, Tremelimumab, Olaparib, Cobimetinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRDF holds $39.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.8M/quarter from operations, an estimated runway of 11.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRDF files for a raise →

👥 Who Owns CRDF

Insiders 2.9% Institutions (112 holders) 20.5% Public and other holders 76.6%
HolderTypeShares% of sharesAs of
Highbridge Capital Management, LLC Institution (13G, 5%+) 4,761,905 6.12% 2026-09-30
Gary W Pace
Director · +1.25M options
Insider 2,043,661 2.63% 2026-07-14
James E. Levine
Chief Financial Officer · +1.30M options
Insider 67,716 0.09% 2024-12-16
Mani Mohindru
Chief Executive Officer, Director · +1.67M options
Insider 59,067 0.08% 2026-07-14
Brigitte Ute Lindsay
Chief Accounting Officer · +1.03M options
Insider 27,431 0.04% 2026-01-27
Renee P Tannenbaum
Director · +506,298 options
Insider 20,000 0.03% 2024-12-12
Joshua B Muntner
Chief Financial Officer · +487,150 options
Insider 500 0.00% 2026-04-06

Share count 77,795,249 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRDF picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRDF and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.